Wegovy and eye side effects: what you should know

Step 1: understand why eye concerns came under the spotlight

In 2024, a study published in the journal JAMA Ophthalmology reported a higher rate of NAION diagnoses among people with type 2 diabetes or obesity who were taking semaglutide compared with those on other medicines. NAION is an abrupt loss of vision caused by interrupted blood supply to the optic nerve. It is rare in the general population, and the study could not confirm that semaglutide caused it, only that the association existed in this particular dataset. The overlap between NAION and vascular risk factors makes causation genuinely difficult to untangle, because the same conditions that lead people to start Wegovy also raise the baseline risk of optic nerve events.

The MHRA and the European Medicines Agency subsequently reviewed the signal. As of summer 2026, NAION is listed as a possible risk under investigation in Wegovy's prescribing information, but regulators have not concluded it is a direct drug effect. That review is ongoing. The longer-term picture of eye damage risk will become clearer as post-marketing surveillance data accumulate.

Until then, the sensible step is transparency: tell your prescriber about any history of eye conditions before starting treatment.

Step 2: know the eye symptoms that need urgent attention

Temporary blurred vision is acknowledged on the NHS semaglutide medicines page as a side effect to be aware of, typically mild and transient. But certain symptoms are in a different category and demand same-day or emergency care.

Call 999 or go to A&E immediately if you notice any of the following while taking Wegovy: sudden loss of vision in one or both eyes, a dark patch or shadow that appears out of nowhere across your visual field, or eye pain accompanied by redness. These can indicate NAION or other acute vascular events that injure the optic nerve. There is no reliable way to reverse NAION once it has progressed, which is why speed of assessment matters.

Worsening diabetic retinopathy is a separate but related concern. Rapid drops in blood glucose (which can accompany fast weight loss) have long been associated with retinopathy changes. If you have a history of diabetic retinopathy, your eye specialist and your weight-management prescriber should be in contact. The relationship between Wegovy and intraocular pressure is another area where early monitoring makes practical sense.

Step 3: put NAION risk in context before making a treatment decision

Absolute numbers matter here. The JAMA Ophthalmology study found roughly 8.9 cases of NAION per 10,000 people taking semaglutide over a 36-month period in the obesity group, compared with roughly 1.8 per 10,000 in the comparator group. That is a meaningful relative difference in a study that cannot prove causation, not an everyday occurrence. For most people using Wegovy, significant visual problems do not develop. The broader picture of semaglutide and eyesight includes much more common, temporary issues such as blurred vision that resolve without intervention.

If you wear glasses, you may notice your prescription feels slightly off as your weight changes, this happens with many medicines that alter fluid balance and is generally not a sign of structural eye damage. A straightforward optician visit can confirm it. The occasional eye-twitch reports associated with GLP-1 medicines likely fall into a similar category: benign, usually related to fatigue or dehydration rather than nerve damage.

None of this means ignoring eye health once you start treatment. An eye test before you begin is reasonable, particularly if you have diabetes, hypertension, or a family history of glaucoma. Your prescriber can advise on the right monitoring schedule, it is one of the practical questions covered during a consultation.

Step 4: how this fits into a clinically supervised treatment plan

The clinical review at a regulated service is where eye history gets factored in properly. At nume, a GPhC-registered Independent Prescriber reads your answers personally (not a form processed by software) on the same day you submit. If you have disclosed a history of retinal disease or optic nerve problems, the prescriber assesses whether Wegovy is appropriate, at what pace to titrate, and what monitoring to put in place. You can read more about our clinical approach on the about us page.

People who are already on treatment elsewhere and want to transfer can explore the process through how to get Wegovy through a regulated UK pharmacy; clinical re-review always applies. If you have a specific question our prescribers can help with, the FAQs are a reasonable first stop, or you can reach the team directly via the contact page.

For anyone weighing up GLP-1 treatment more broadly, the weight-loss treatment overview covers how Wegovy sits alongside other licensed options. When you are ready, a free consultation with our prescribers is the right place to start, they can take your eye history, your full medical picture, and any current medicines into account before making a recommendation.